TissueTech CEO and leadership

Scheffer C. G. Tseng, Scheffer MD, PhD co-founded Bio-Tissue, Inc. in 1997 and serves as its Chief Scientific Officer. Dr. Tseng serves as Executive Officer and Director of Tissuetech, Inc. He is a world-renowned surgeon in ocular surface reconstruction. He served as Chair Professor at Bascom Palmer Eye Institute, University of Miami School of Medicine. He pioneered limbal stem cell transplantation and popularized the concept of using the CRYOTEKâ ¢ process to preserve the natural wound healing properties of amniotic membrane for ocular surface reconstruction. His research focus during the last 10 years has been to identify the active biological components of human amniotic membrane, to develop alternative products in delivering the efficacies of its natural healing properties, and to expand the benefits of its clinical applications. He is a well-published physician scientist with over 300 peer-reviewed clinical and scientific papers. Dr. Tseng received his M.D. at National Taiwan University and his Ph.D. in Experimental Pathology at the University of California, San Francisco. He completed his residency for Ophthalmology at the Wilmer Eye Institute at Johns Hopkins and his fellowship in Cornea and External Diseases at Massachusetts Eye and Ear Infirmary.

Amy H. Tseng, MBA, CPA serves as the Chief Executive Officer and President at Bio-Tissue, Inc. Amy Tseng serves as the President and Chief Executive Officer of Tissuetech, Inc. An accomplished CPA with experience at both Ernst & Young and Price Waterhouse, Amy Tseng founded Bio-Tissue in 1997 with the vision of re-introducing amniotic membrane as a platform technology for the treatment of ocular surface diseases. Since its inception, Amy Tseng has carried this mission, building Bio-Tissue into the industry leader. Through excellent financial and corporate management, she has guided Bio-Tissue through impressive levels of annual growth. In addition to her instrumental role in founding Bio-Tissue, Amy Tseng continues to lead and drive it, not only to provide the highest quality product possible, but also to continuously improve methods of wound care management. She serves as a Director of Tissuetech, Inc. Amy Tseng graduated from the National Taiwan University and received her MBA from the University of Southern California. She is also certified as a CPA in several states, including Florida and California.

Michael Cornelius joined TissueTech as Chief Financial Officer in 2014 with more than 25 years of experience in public accounting and public and private corporations. Michael Cornelius was previously with Stiefel Laboratories, serving as its Chief Financial Officer. Stiefel Laboratories was the largest privately-held dermatology company in the world, before it was acquired by GlaxoSmithKline in 2009. Mike began his career with the international accounting and consulting firm, Grant Thornton, where he specialized in US and International tax planning and also held senior level finance positions with IVAX Corporation and Sunglass Hut International. Mike holds a Bachelor of Science in Business Administration from Indiana University of Pennsylvania and is a Certified Public Accountant.

Top-Producing Executive with substantial selling and managing experience and proven track record of talent development, rapid sales growth and organizational scale. Combined experience in sales leadership, marketing, strategic market development and key opinion leader management. Consistent success in identifying personnel opportunities, market expansion and accelerated growth.

Specialties: executive management, strategy, revenue growth and leadership

Scheffer C. G. Tseng, Scheffer MD, PhD co-founded Bio-Tissue, Inc. in 1997 and serves as its Chief Scientific Officer. Dr. Tseng serves as Executive Officer and Director of Tissuetech, Inc. He is a world-renowned surgeon in ocular surface reconstruction. He served as Chair Professor at Bascom Palmer Eye Institute, University of Miami School of Medicine. He pioneered limbal stem cell transplantation and popularized the concept of using the CRYOTEKâ ¢ process to preserve the natural wound healing properties of amniotic membrane for ocular surface reconstruction. His research focus during the last 10 years has been to identify the active biological components of human amniotic membrane, to develop alternative products in delivering the efficacies of its natural healing properties, and to expand the benefits of its clinical applications. He is a well-published physician scientist with over 300 peer-reviewed clinical and scientific papers. Dr. Tseng received his M.D. at National Taiwan University and his Ph.D. in Experimental Pathology at the University of California, San Francisco. He completed his residency for Ophthalmology at the Wilmer Eye Institute at Johns Hopkins and his fellowship in Cornea and External Diseases at Massachusetts Eye and Ear Infirmary.

Amy H. Tseng, MBA, CPA serves as the Chief Executive Officer and President at Bio-Tissue, Inc. Amy Tseng serves as the President and Chief Executive Officer of Tissuetech, Inc. An accomplished CPA with experience at both Ernst & Young and Price Waterhouse, Amy Tseng founded Bio-Tissue in 1997 with the vision of re-introducing amniotic membrane as a platform technology for the treatment of ocular surface diseases. Since its inception, Amy Tseng has carried this mission, building Bio-Tissue into the industry leader. Through excellent financial and corporate management, she has guided Bio-Tissue through impressive levels of annual growth. In addition to her instrumental role in founding Bio-Tissue, Amy Tseng continues to lead and drive it, not only to provide the highest quality product possible, but also to continuously improve methods of wound care management. She serves as a Director of Tissuetech, Inc. Amy Tseng graduated from the National Taiwan University and received her MBA from the University of Southern California. She is also certified as a CPA in several states, including Florida and California.

Amy H. Tseng, MBA, CPA serves as the Chief Executive Officer and President at Bio-Tissue, Inc. Amy Tseng serves as the President and Chief Executive Officer of Tissuetech, Inc. An accomplished CPA with experience at both Ernst & Young and Price Waterhouse, Amy Tseng founded Bio-Tissue in 1997 with the vision of re-introducing amniotic membrane as a platform technology for the treatment of ocular surface diseases. Since its inception, Amy Tseng has carried this mission, building Bio-Tissue into the industry leader. Through excellent financial and corporate management, she has guided Bio-Tissue through impressive levels of annual growth. In addition to her instrumental role in founding Bio-Tissue, Amy Tseng continues to lead and drive it, not only to provide the highest quality product possible, but also to continuously improve methods of wound care management. She serves as a Director of Tissuetech, Inc. Amy Tseng graduated from the National Taiwan University and received her MBA from the University of Southern California. She is also certified as a CPA in several states, including Florida and California.